Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 13,015 shares at $0.67 ($9K) on 2019-01-23, disclosed to the SEC on 2019-01-24.
Open-market purchase of $9k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.68 | 10,749 | $7K | 82.8% |
| 2 | $0.67 | 2,266 | $2K | 17.2% |
| Total | $0.68 avg | 13,015 | $9K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |